CN113164573B - 包含修饰的MHC II类DRα1结构域的重组多肽及其应用方法 - Google Patents

包含修饰的MHC II类DRα1结构域的重组多肽及其应用方法 Download PDF

Info

Publication number
CN113164573B
CN113164573B CN201980079085.8A CN201980079085A CN113164573B CN 113164573 B CN113164573 B CN 113164573B CN 201980079085 A CN201980079085 A CN 201980079085A CN 113164573 B CN113164573 B CN 113164573B
Authority
CN
China
Prior art keywords
domain
polypeptide
binding
seq
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980079085.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113164573A (zh
Inventor
A·范登巴克
R·梅萨-罗梅罗
H·奥夫内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
US Department of Veterans Affairs
Original Assignee
Oregon Health and Science University
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University, US Department of Veterans Affairs filed Critical Oregon Health and Science University
Publication of CN113164573A publication Critical patent/CN113164573A/zh
Application granted granted Critical
Publication of CN113164573B publication Critical patent/CN113164573B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980079085.8A 2018-10-05 2019-10-04 包含修饰的MHC II类DRα1结构域的重组多肽及其应用方法 Active CN113164573B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741941P 2018-10-05 2018-10-05
US62/741,941 2018-10-05
PCT/US2019/054850 WO2020072992A1 (en) 2018-10-05 2019-10-04 Recombinant polypeptides comprising modified mhc class ii drα1 domains and methods of use

Publications (2)

Publication Number Publication Date
CN113164573A CN113164573A (zh) 2021-07-23
CN113164573B true CN113164573B (zh) 2024-05-31

Family

ID=68296863

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980079085.8A Active CN113164573B (zh) 2018-10-05 2019-10-04 包含修饰的MHC II类DRα1结构域的重组多肽及其应用方法

Country Status (8)

Country Link
US (1) US11945855B2 (https=)
EP (1) EP3860644A1 (https=)
JP (1) JP7511551B2 (https=)
KR (1) KR102925681B1 (https=)
CN (1) CN113164573B (https=)
AU (1) AU2019355062B2 (https=)
CA (1) CA3114446A1 (https=)
WO (1) WO2020072992A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719466A1 (en) * 2023-05-26 2026-04-08 Oregon Health & Science University Treatment of cancer with drq polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044982A2 (en) * 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
CN104105503A (zh) * 2012-01-06 2014-10-15 俄勒冈健康科学大学 部分mhc构建体及使用方法
WO2018087597A1 (en) * 2016-11-09 2018-05-17 Uti Limited Partnership Recombinant pmhc class ii molecules

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
US20130309229A1 (en) 2011-01-28 2013-11-21 The United States Government As Represented By The Department Of Veterans Affairs Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
US9260506B2 (en) 2011-04-07 2016-02-16 Oregon Health & Science University Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)
WO2015051328A1 (en) 2013-10-03 2015-04-09 Oregon Health & Science University TREATMENT OF ISCHEMIC STROKE WITH DRα1-MOG-35-55
EP3052526A4 (en) 2013-10-03 2017-04-19 Oregon Health & Science University Recombinant polypeptides comprising mhc class ii 1 domains
WO2017070569A1 (en) 2015-10-23 2017-04-27 Oregon Health & Science University Compounds that bind macrophage migration inhibitory factor
US10689446B2 (en) 2016-06-22 2020-06-23 Oregon Health & Science University Recombinant CD74 polypeptides
US20180271935A1 (en) 2017-03-15 2018-09-27 Oregon Health & Science University Dralpha1-mog-35-55 treatment of traumatic brain injury

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044982A2 (en) * 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
CN104105503A (zh) * 2012-01-06 2014-10-15 俄勒冈健康科学大学 部分mhc构建体及使用方法
JP2015505315A (ja) * 2012-01-06 2015-02-19 オレゴン ヘルス アンド サイエンス ユニバーシティ 部分的ｍｈｃコンストラクト及びその使用方法
WO2018087597A1 (en) * 2016-11-09 2018-05-17 Uti Limited Partnership Recombinant pmhc class ii molecules

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis;Roberto Meza-Romero等;《J Immunol》;第192卷(第9期);第4164-4173页 *
HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection;Gil Benedek等;《J Neuroinflammation》;第12卷;123 *
Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct;Roberto Meza-Romero等;《Metab Brain Dis》;第34卷(第1期);第153-164页 *
Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity;Jianya Y Huan等;《J Chem Technol Biotechnol》;第80卷(第1期);第2-12页 *
彭真等.多发性硬化动物模型研究进展.《动物医学进展》.2017,第38卷(第4期),108-112. *

Also Published As

Publication number Publication date
CN113164573A (zh) 2021-07-23
JP7511551B2 (ja) 2024-07-05
JP2022504217A (ja) 2022-01-13
EP3860644A1 (en) 2021-08-11
WO2020072992A1 (en) 2020-04-09
US20210380660A1 (en) 2021-12-09
AU2019355062B2 (en) 2025-12-18
US11945855B2 (en) 2024-04-02
CA3114446A1 (en) 2020-04-09
KR20210071019A (ko) 2021-06-15
KR102925681B1 (ko) 2026-02-10
AU2019355062A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP5738333B2 (ja) 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド
EP1675607B1 (en) Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
US20150044245A1 (en) Partial mhc constructs and methods of use
EP3384924A1 (en) Uses of soluble ctla4 mutant molecules
WO2018170096A1 (en) Use of a cd4/cd8 bispecific antibody for the treatment of diabetes
JP2008537736A (ja) 抗原特異的ｔ細胞の操作に有用な組換えｍｈｃ分子
KR20260021695A (ko) 이기능성 결합 폴리펩타이드
CN107441480A (zh) 多肽及其作为用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的药物的用途
WO2015092077A1 (en) Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
JP2009029833A (ja) Ｃｄ２８／ｃｔｌａ−４阻害性ペプチド模倣物、それらの医薬組成物、およびそれらを使用する方法
CN118678964A (zh) Ig样融合蛋白及其用途
WO1997035879A1 (en) Myelin oligodendrocyte glycoprotein peptides and uses thereof
US10316075B2 (en) Recombinant polypeptides comprising MHC class II α1 domains
CN113164573B (zh) 包含修饰的MHC II类DRα1结构域的重组多肽及其应用方法
EP2945966B1 (en) Peptide
US10525101B2 (en) Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
JPH10501210A (ja) 糖尿病に対するペプチドおよび方法
NO320773B1 (no) Isolert polypeptid og vektor omfattende dette, artrittogent peptid av polypeptidet og sammensetning omfattende dette for forebyggelse og behandling av reumatoid artritt.
JP7685766B2 (ja) 抗ｉｄｅ抗体およびその使用
HK1211596B (en) Peptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant